Published in Cancer Sci on May 01, 2009
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Therapeutic antibody targeting of individual Notch receptors. Nature (2010) 4.56
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med (2011) 4.37
Mutations in NOTCH2 cause Hajdu-Cheney syndrome, a disorder of severe and progressive bone loss. Nat Genet (2011) 3.97
The Notch signalling system: recent insights into the complexity of a conserved pathway. Nat Rev Genet (2012) 2.77
Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol (2010) 2.58
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med (2012) 1.90
The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest (2012) 1.86
Notch signaling in human development and disease. Semin Cell Dev Biol (2012) 1.79
From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell (2014) 1.70
Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med (2012) 1.66
The double-edged sword of Notch signaling in cancer. Semin Cell Dev Biol (2012) 1.53
Notch and disease: a growing field. Semin Cell Dev Biol (2012) 1.48
ADAM10 is essential for Notch2-dependent marginal zone B cell development and CD23 cleavage in vivo. J Exp Med (2010) 1.47
Regulation of mammalian Notch signaling and embryonic development by the protein O-glucosyltransferase Rumi. Development (2011) 1.42
Cutaneous papillomavirus E6 oncoproteins associate with MAML1 to repress transactivation and NOTCH signaling. Oncogene (2012) 1.27
Gamma secretase inhibitors of Notch signaling. Onco Targets Ther (2013) 1.21
Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. Leukemia (2013) 1.14
Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells. Trends Mol Med (2009) 1.07
Notch signaling in glioblastoma: a developmental drug target? BMC Med (2010) 1.04
Current views on the role of Notch signaling and the pathogenesis of human leukemia. BMC Cancer (2011) 1.03
Mutations in NOTCH2 in patients with Hajdu-Cheney syndrome. Osteoporos Int (2013) 1.01
Notch signaling in skeletal health and disease. Eur J Endocrinol (2013) 1.00
Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood (2015) 0.99
MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. Leukemia (2011) 0.98
Role of glycans and glycosyltransferases in the regulation of Notch signaling. Glycobiology (2010) 0.97
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer (2015) 0.94
Hajdu-Cheney syndrome: a review. Orphanet J Rare Dis (2014) 0.93
The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection. Haematologica (2014) 0.92
The truncate mutation of Notch2 enhances cell proliferation through activating the NF-κB signal pathway in the diffuse large B-cell lymphomas. PLoS One (2014) 0.90
The emergence of ADAM10 as a regulator of lymphocyte development and autoimmunity. Mol Immunol (2011) 0.88
A microRNA-mediated regulatory loop modulates NOTCH and MYC oncogenic signals in B- and T-cell malignancies. Leukemia (2014) 0.87
Hes1 suppresses acute myeloid leukemia development through FLT3 repression. Leukemia (2014) 0.87
Notch signaling: its roles and therapeutic potential in hematological malignancies. Oncotarget (2016) 0.87
Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. Neuro Oncol (2010) 0.86
Increased LEF1 expression and decreased Notch2 expression are strong predictors of poor outcomes in colorectal cancer patients. Dis Markers (2013) 0.85
The differential expression of IL-4 and IL-13 and its impact on type-2 immunity. Cytokine (2015) 0.84
NOTCH1 mutations influence survival in chronic lymphocytic leukemia patients. BMC Cancer (2013) 0.84
Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann Hematol (2014) 0.83
Notch Signaling and the Skeleton. Endocr Rev (2016) 0.82
The NOTCH signaling pathway in normal and malignant blood cell production. J Cell Commun Signal (2015) 0.80
Moving towards personalised therapy in head and neck squamous cell carcinoma through analysis of next generation sequencing data. Eur J Cancer (2016) 0.79
The challenge of targeting notch in hematologic malignancies. Front Pediatr (2014) 0.78
Hajdu Cheney Syndrome; report of a novel NOTCH2 mutation and treatment with denosumab. Bone (2016) 0.77
Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus. Cell Death Dis (2015) 0.77
Hajdu-Cheney Syndrome, a Disease Associated with NOTCH2 Mutations. Curr Osteoporos Rep (2016) 0.77
Animal models to study the mutational landscape for oral cavity and oropharyngeal cancers. J Oral Maxillofac Res (2013) 0.77
Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses. Oncotarget (2016) 0.77
The role of Notch and gamma-secretase inhibition in an ovarian cancer model. Anticancer Res (2013) 0.76
Disease-specific mutations in mature lymphoid neoplasms: recent advances. Cancer Sci (2014) 0.76
Notch2 transduction by feline leukemia virus in a naturally infected cat. J Vet Med Sci (2013) 0.75
The Link between Autoimmunity and Lymphoma: Does NOTCH Signaling Play a Contributing Role? Front Oncol (2015) 0.75
BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. Cancer Discov (2017) 0.75
Oncogenic Notch signaling in T-cell and B-cell lymphoproliferative disorders. Curr Opin Hematol (2016) 0.75
A jagged road to lymphoma aggressiveness. Cancer Cell (2014) 0.75
Frequent pathway mutations of splicing machinery in myelodysplasia. Nature (2011) 11.44
A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res (2005) 11.02
ATP drives lamina propria T(H)17 cell differentiation. Nature (2008) 8.02
Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res (2004) 7.96
RET, ROS1 and ALK fusions in lung cancer. Nat Med (2012) 6.76
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20
Oncogenic mutations of ALK kinase in neuroblastoma. Nature (2008) 5.80
Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet (2013) 4.61
Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet (2007) 4.52
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res (2005) 4.42
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res (2007) 4.41
KIF5B-RET fusions in lung adenocarcinoma. Nat Med (2012) 4.38
A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol (2011) 4.26
Frequent inactivation of A20 in B-cell lymphomas. Nature (2009) 4.22
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 4.20
Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature (2010) 4.12
AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med (2004) 4.00
Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell (2004) 3.98
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature (2009) 3.80
Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. Immunity (2003) 3.73
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol (2012) 3.57
Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med (2015) 3.42
Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res (2010) 3.40
New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer (2002) 3.38
The role of ICOS in the CXCR5+ follicular B helper T cell maintenance in vivo. J Immunol (2005) 3.23
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol (2011) 3.10
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med (2003) 3.00
NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J (2003) 2.97
Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res (2005) 2.97
Notch1 but not Notch2 is essential for generating hematopoietic stem cells from endothelial cells. Immunity (2003) 2.94
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (2002) 2.88
A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo. J Exp Med (2007) 2.82
Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood (2002) 2.72
Tumor necrosis factor alpha (TNFalpha) induces the unfolded protein response (UPR) in a reactive oxygen species (ROS)-dependent fashion, and the UPR counteracts ROS accumulation by TNFalpha. J Biol Chem (2005) 2.71
TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem (2003) 2.69
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68
Periostin is essential for cardiac healing after acute myocardial infarction. J Exp Med (2008) 2.68
CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res (2002) 2.60
Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res (2011) 2.59
Real-time identification of liver cancers by using indocyanine green fluorescent imaging. Cancer (2009) 2.54
Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers. Cancer Cell (2012) 2.53
CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res (2005) 2.53
Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. Hum Mol Genet (2006) 2.51
Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res (2002) 2.49
MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res (2010) 2.48
Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet (2010) 2.47
Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood (2010) 2.45
Retracted FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest (2011) 2.44
Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood (2009) 2.43
Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol (2007) 2.43
Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J Clin Invest (2011) 2.40
Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene (2005) 2.36
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A (2011) 2.35
Delta1-Notch3 interactions bias the functional differentiation of activated CD4+ T cells. Immunity (2003) 2.34
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol (2011) 2.34
Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood (2007) 2.31
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30
Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1-->3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol (2004) 2.28